Agomelatine

• Dry-fill capsules (25 mg per capsule, 60-count / 1.5 g total)
• 1 gram powder

Research indicates Agomelatine may influence neurological and circadian systems through dual-pathway modulation: This combined mechanism has made Agomelatine a compound of interest in research models where circadian misalignment and mood dysregulation overlap.

• Agonism of melatonin MT1 and MT2 receptors
• Antagonism of serotonin 5-HT2C receptors
• Resynchronization of circadian-rhythm signaling
• Modulation of dopamine and norepinephrine release in frontal cortical regions
• Support of sleep-wake-cycle stability without classic sedative effects

Agomelatine is commonly studied in

• Circadian-rhythm and chronobiology research
• Sleep-onset and sleep-quality models
• Mood and affective-disorder pathways
• Stress-response and emotional-regulation studies
• Depression-related neurochemical research
• Cognitive performance under sleep-deprivation conditions

Reported or historically noted findings include: Because of hepatic-metabolism considerations, Agomelatine is often studied with attention to liver-function markers in longer-duration models.

• Mild headache
• Gastrointestinal discomfort
• Transient dizziness
• Fatigue during initial exposure periods
• Liver-enzyme elevation noted in some clinical research contexts

Agomelatine is often explored alongside compounds targeting sleep, circadian rhythm, or mood stability